Prostate cancer cell phenotypes based on AGR2 and CD10 expression

• Published in: Modern pathology Vol. 26; no. 6; pp. 849 - 859
• Main Authors: Ho, Melissa E, Quek, Sue-Ing, True, Lawrence D, Morrissey, Colm, Corey, Eva, Vessella, Robert L, Dumpit, Ruth, Nelson, Peter S, Maresh, Erin L, Mah, Vei, Alavi, Mohammed, Kim, Sara R, Bagryanova, Lora, Horvath, Steve, Chia, David, Goodglick, Lee, Liu, Alvin Y
• Format: Journal Article
• Language: English
• Published: New York Elsevier Inc 01.06.2013; Nature Publishing Group US; Elsevier Limited
• Subjects: 692/53/2422; 692/699/2768/466; 692/700/139/422; AGR2; Animals; Antigens; Biomarkers, Tumor - metabolism; Biopsy; bone and soft tissue metastases; Bone Neoplasms - genetics; Bone Neoplasms - metabolism; Bone Neoplasms - mortality; Bone Neoplasms - secondary; cancer cell phenotypes; Carcinoma - genetics; Carcinoma - metabolism; Carcinoma - mortality; Carcinoma - secondary; CD10; Disease-Free Survival; Genotype & phenotype; Heterografts; Humans; Immunohistochemistry; Immunophenotyping; Kaplan-Meier Estimate; Laboratory Medicine; Lymphatic Metastasis; Male; Medical prognosis; Medicine; Medicine & Public Health; Metastasis; Mice; Mice, Inbred BALB C; Mice, Nude; Mucoproteins; Multivariate Analysis; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Transplantation; Neprilysin - metabolism; Oncogene Proteins; original-article; Pathology; patient stratification; Patients; Phenotype; Proportional Hazards Models; Prostate cancer; Prostatic Neoplasms - genetics; Prostatic Neoplasms - metabolism; Prostatic Neoplasms - mortality; Prostatic Neoplasms - pathology; Proteins; Proteins - metabolism; Risk Factors; Time Factors; Tissue Array Analysis; Tumors; Urology; xenografts; Los Angeles California; United States > US; California; prostate cancer; cancer cell phenotypes; xenografts; AGR2; bone and soft tissue metastases; patient stratification; CD10
• ISSN: 0893-3952; 1530-0285
• DOI: 10.1038/modpathol.2012.238

The combination of expression patterns of AGR2 (anterior gradient 2) and CD10 by prostate cancer provided four phenotypes that correlated with clinical outcome. Based on immunophenotyping, CD10lowAGR2high, CD10highAGR2high, CD10lowAGR2low, and CD10highAGR2low were distinguished. AGR2+ tumors were associated with longer recurrence-free survival and CD10+ tumors with shorter recurrence-free survival. In high-stage cases, the CD10lowAGR2high phenotype was associated with a ninefold higher recurrence-free survival than the CD10highAGR2low phenotype. The CD10highAGR2high and CD10lowAGR2low phenotypes were intermediate. The CD10highAGR2low phenotype was most frequent in high-grade primary tumors. Conversely, bone and other soft tissue metastases, and derivative xenografts, expressed more AGR2 and less CD10. AGR2 protein was readily detected in tumor metastases. The CD10highAGR2low phenotype in primary tumors is predictive of poor outcome; however, the CD10lowAGR2high phenotype is more common in metastases. It appears that AGR2 has a protective function in primary tumors but may have a role in the distal spread of tumor cells.